Skip to Content

Spiriva Respimat Approval History

Spiriva Respimat (tiotropium bromide) is a long-acting muscarinic antagonist (LAMA) indicated for the long-term, maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Development History and FDA Approval Process for Spiriva Respimat

Feb 16, 2017Approval FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
Sep 16, 2015Approval FDA Approves Spiriva Respimat (tiotropium) for Maintenance Treatment of Asthma in Adults and Adolescents
Sep 25, 2014Approval FDA Approves Spiriva Respimat (tiotropium) for the Maintenance Treatment of COPD

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.